Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.57 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MPL | P40238 | 1/20 | 0.41 |
| ▸ | EIF4E | P06730 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25242184 | 0.83 | RAB9A (0.61) | ABL1RAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL19627004 | 0.82 | ABL1 (0.59) | ABL1RAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL19625338 | 0.78 | ABL1 (0.55) | ABL1KMORAB9ANPC1ALDH1A1 | |
| SCHEMBL3971680 | 0.75 | ABL1 (0.65) | ABL1RAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL14754382 | 0.75 | KMO (0.47) | ABL1KMOMEN1KMT2AKDM4E | |
| SCHEMBL3761118 | 0.74 | RAB9A (0.66) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL3823252 | 0.74 | RAB9A (0.58) | ABL1RAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL3174725 | 0.74 | RAB9A (0.68) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL28673241 | 0.74 | PTGS2 (0.50) | ABL1RAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL3765806 | 0.72 | CYP19A1 (0.60) | ABL1RAB9ANPC1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501031-B | Oxazolidone derivatives as PR modulators | WYETH (US) | 2012-02-01 | — | — | CN | disclosed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| CN-101501031-A | Oxazolidone derivatives as pr modulators | WYETH CORP (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | MC2R, NPY1R, PRLHR | ABL1 4372/4885KMO 643/4885RAB9A 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.